Trulicity (Dulaglutide) for Adults 65 and Older: School, Work, and Activity Considerations

Does age over 65 change the dose or the schedule?

No. The label's adult dosing has no age-specific step, and it reports no clinically relevant pharmacokinetic effect of age [1]. Dulaglutide's half-life is about 5 days, with bioavailability of 65% at 0.75 mg and 47% at 1.5 mg [1].

The adult schedule is the same at any age. Start at 0.75 mg once weekly; after 4 weeks the dose may go to 1.5 mg for additional glycemic control; further increases come in 1.5 mg steps after at least 4 weeks on the current dose, up to a maximum of 4.5 mg once weekly [1].

Missed doses have their own rule. The label says to give a missed dose as soon as possible if at least 3 days (72 hours) remain before the next scheduled dose; if less than 3 days remain, the missed dose is skipped and the next dose goes on the regularly scheduled day [1]. The day of weekly administration can be changed when the last dose was given 3 or more days before the new day [1]. That matters for a semester timetable, a shift rotation or a weekly volunteer commitment.

Fitting a weekly injection around work or class

The label allows the injection at any time of day, with or without food, into the abdomen, thigh or upper arm, rotating sites with each dose [1]. When Trulicity is used with insulin, the label says the two are given as separate injections and never mixed; the same body region is acceptable, but the injections should not be adjacent to each other [1].

The label says to follow the dose escalation to reduce the risk of gastrointestinal adverse reactions [1]. In the 36-week dose-ranging trial of 1,842 adults on metformin, nausea was reported by 13.4% on 1.5 mg, 15.6% on 3 mg and 16.4% on 4.5 mg, and vomiting by 5.6%, 8.3% and 9.3% [1].

What GI side effects mean for a working day

Nausea, diarrhea, vomiting, abdominal pain and decreased appetite are the most common adverse reactions in the adult placebo-controlled pool (placebo N=568, 0.75 mg N=836, 1.5 mg N=834; mean exposure 23.8 weeks). Rates for placebo / 0.75 mg / 1.5 mg were [1]:

• Nausea: 5.3% / 12.4% / 21.1%
• Diarrhea: 6.7% / 8.9% / 12.6%
• Vomiting: 2.3% / 6.0% / 12.7%
• Abdominal pain: 4.9% / 6.5% / 9.4%
• Decreased appetite: 1.6% / 4.9% / 8.6%
• Fatigue (not a GI reaction): 2.6% / 4.2% / 5.6%

Any GI reaction was reported by 21% on placebo, 32% on 0.75 mg and 41% on 1.5 mg, and 0.2%, 1.3% and 3.5% stopped treatment for GI reasons [1]. Investigators graded the GI reactions as mild in 58% (0.75 mg) and 48% (1.5 mg) of cases, moderate in 35% and 42%, and severe in 7% and 11% [1]. Severe GI reactions were reported in 1.4% of placebo patients, 2.2% on 0.75 mg and 4.3% on 1.5 mg, and Trulicity is not recommended in patients with severe gastroparesis [1].

For older adults specifically, a review of completed Phase 4 trials of GLP-1 receptor agonists in people aged 65 and older found 37 studies, 7 of them of dulaglutide, with a median enrollment of 180. Across these trials, GI intolerance was reported at 15% to 30%, injection-site reactions at 5% or less, and hypoglycemia at under 5% [2].

The label warning that applies when nausea or vomiting keeps someone home is volume depletion. Acute kidney injury has been reported with GLP-1 receptor agonists including Trulicity, mostly in patients who had GI reactions leading to dehydration, and the label says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].

Hypoglycemia when insulin or a sulfonylurea is also on the schedule

When added to metformin, hypoglycemia below 54 mg/dL occurred in 0.7% of patients receiving Trulicity 1.5 mg versus 0% receiving placebo, and 3.3% versus 0% when added to glimepiride [1]. With insulin glargine the rate was 14.7% on Trulicity 1.5 mg versus 9.3% on placebo [1]. In a 78-week trial, hypoglycemia below 54 mg/dL occurred in 20% and 21% of patients taking 0.75 mg and 1.5 mg with a sulfonylurea [1].

The label advises considering a reduction in the insulin or sulfonylurea dose when Trulicity is started, and informing patients on those drugs about the risk and the signs and symptoms of hypoglycemia [1].

Physical activity: what the label does and does not set

Trulicity's first indication is as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes [1]. The label sets no activity restrictions. Its relevant warnings are GI reactions with volume depletion, hypoglycemia with insulin or an insulin secretagogue, and pulmonary aspiration during general anesthesia or deep sedation [1].

Decreased appetite was reported by 4.9% of adults on 0.75 mg and 8.6% on 1.5 mg versus 1.6% on placebo [1]. Trulicity is not approved for weight loss or chronic weight management; no obesity indication appears in the label [1].

Procedures and sedation

The label warns about pulmonary aspiration during general anesthesia or deep sedation in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures, and says to inform healthcare providers of any planned surgeries or procedures [1].

What the heart-outcome trial looked at

REWIND was a multicentre, randomised, double-blind, placebo-controlled trial that assigned adults aged at least 50 years with type 2 diabetes and either a previous cardiovascular event or cardiovascular risk factors to weekly subcutaneous dulaglutide 1.5 mg or placebo, with follow-up at least every 6 months [3]. Its primary outcome was the first occurrence of non-fatal myocardial infarction, non-fatal stroke, or death from cardiovascular causes [3].

The population matches the label's cardiovascular indication, which covers adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, not only those with a prior event [1].

What the data do not describe

The geriatric data describe tolerability rather than daily function: the Phase 4 review reported GI intolerance at 15% to 30% and hypoglycemia under 5% across GLP-1 receptor agonist trials in older adults [2]. Class attendance, work productivity, driving performance and fall rates in adults 65 and older taking dulaglutide are not among the outcomes reported in the label data or trials described here.